Drug intelligence / Profile preview

EGTX003

Development stage: Preclinical
Lead developer: Engitix Therapeutics
Modality: Small Molecules
Administration: Unspecified (not Yet Determined Or Disclosed)[1]

Overview

EGTX003 is an investigational drug being developed by Engitix for the treatment of fibrosis and inflammation. It is classified as both an anti-inflammatory and antifibrotic agent. The precise mechanism of action has not been defined or disclosed publicly as of the latest updates. The drug is considered a new molecular entity and remains in early research stages, with preclinical development focused on metabolic dysfunction-associated steatotic liver disease (MASLD), fibrosis, and general inflammatory conditions[1][2].

Beyond the preview

Go deeper on EGTX003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EGTX003.

Explore the full profile